The Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School will host Should Congress Repeal the McCarran-Ferguson Act? on Friday, November 12, 2010. There are a limited number of spaces available for specialists in the field who would like to attend. Requests for attendance will be accepted on the basis of availability. If you would like to attend or have any questions, please email firstname.lastname@example.org Please note that unfortunately, funding for travel to Cambridge is not available and must be provided by attendees home institution.
In 1944, the U.S. Supreme Court, in United States v. South-Eastern Underwriters Association, held that the Commerce Clause authorized the federal government to regulate insurance companies. The next year, in direct response, Congress passed the McCarran-Ferguson Act, effectively shielding the business of insurance from federal antitrust regulation, except the regulation of boycott, coercion and intimidation, so long as state law regulates anticompetitive conduct. Shortly thereafter, a debate arose as to whether the federal antitrust law exemption should be repealed. With the recent flurry of federal reform of health care insurance markets, the current debate has centered on whether Congress should repeal the McCarran-Ferguson Act’s antitrust exemption for health care insurers. The one-day conference will bring together regulators, industry actors and academics working in the fields of business, law and economics to discuss the pros and cons of repealing the McCarran-Ferguson Acts federal antitrust exemption for health care insurers.